Search
Tony Keating says the study reveals many issues in the quality of cough recordings, and is not what the company expected.

ResApp crashes on study results

Shares in medical tech company ResApp Health plummeted 77 per cent today on disappointing results of a clinical study on its ResAppDx technology.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 28/09/18

1 year TSR5 year TSR
25thResApp Health213%97%
242ndPeppermint Innovation27%-13%
363rdZelda Therapeutics4%48%
746thAssembleBay-56%-51%
739 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

05/10/17
$65k Bought
16/12/16
$49k Bought
16/12/16
$49k Other
Total value as at the date of the transaction
Source: Morningstar

Revenue

158th↑AssembleBay$1.0m
159th-Cre8tek$1.0m
160th↑ResApp Health$999k
161st↑Zelda Therapeutics$960k
162nd↓Peppermint Innovation$908k
239 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer